UNSPSC 51313426: Dexbrompheniramine maleate

This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H19BrN2.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BPA9UT29BS, chemically known as 2-pyridinepropanamine, gamma-(4-bromophenyl)-n,n-dimethyl-, (s)-, (z)-2-butenedioate (1:1) but more generally known as dexbrompheniramine maleate, which bears US NIH Compound Identifier 6433334. European Medicines Agency schedules Dexbrompheniramine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01626MIG.

UNSPSC 51313426 Dexbrompheniramine maleate is a Commodity code that encompasses individual pharmaceutical products procured by state and local health authorities, typically through bulk purchasing arrangements with authorized wholesalers and direct manufacturers. State and local governments buy specific branded and generic medications under this code to support community health programs, pharmacy benefit management for state employees and beneficiaries, and emergency response initiatives. The issuing bodies soliciting pharmaceuticals include state health and human services agencies, county public health departments, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions. Recent solicitations show state health commissions managing pharmacy benefit programs and county health systems procuring emergency medical supplies alongside routine pharmaceutical inventories, often requiring vendors to maintain FDA compliance, cGMP certification, and drug-supply-chain security protocols.

Recent activity appears concentrated in Florida and Minnesota, with Texas state health authorities issuing exploratory requests for pharmacy program modernization. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023. The Minnesota Department of Administration's Office of State Procurement, administering the MMCAP multistate cooperative purchasing vehicle, released an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026; vendors must maintain relationships with authorized wholesalers including AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., and awards will be based on fixed pricing (10 percent weight), compliance with administrative requirements (10 percent), EDI capability (5 percent), and price competitiveness (75 percent). The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program, indicating state-level interest in alternative pharmaceutical procurement models outside traditional PBM and GPO channels.